- Home
- USIO vs FGEN Comparison
USIO vs FGEN Comparison
Compare USIO & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- FGEN
- Stock Information
- Founded
- USIO 1998
- FGEN 1993
- Country
- USIO United States
- FGEN United States
- Employees
- USIO N/A
- FGEN N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- FGEN Health Care
- Exchange
- USIO Nasdaq
- FGEN Nasdaq
- Market Cap
- USIO 37.6M
- FGEN 45.1M
- IPO Year
- USIO N/A
- FGEN 2014
- Fundamental
- Price
- USIO $1.44
- FGEN $10.91
- Analyst Decision
- USIO Strong Buy
- FGEN Strong Buy
- Analyst Count
- USIO 1
- FGEN 2
- Target Price
- USIO $4.00
- FGEN $146.50
- AVG Volume (30 Days)
- USIO 72.5K
- FGEN 25.5K
- Earning Date
- USIO 11-05-2025
- FGEN 11-03-2025
- Dividend Yield
- USIO N/A
- FGEN N/A
- EPS Growth
- USIO N/A
- FGEN N/A
- EPS
- USIO 0.11
- FGEN N/A
- Revenue
- USIO $83,851,606.00
- FGEN $7,346,000.00
- Revenue This Year
- USIO $8.71
- FGEN N/A
- Revenue Next Year
- USIO $12.48
- FGEN N/A
- P/E Ratio
- USIO $13.28
- FGEN N/A
- Revenue Growth
- USIO 2.05
- FGEN N/A
- 52 Week Low
- USIO $1.24
- FGEN $4.50
- 52 Week High
- USIO $2.92
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- USIO 49.86
- FGEN 47.69
- Support Level
- USIO $1.43
- FGEN $10.59
- Resistance Level
- USIO $1.47
- FGEN $11.22
- Average True Range (ATR)
- USIO 0.05
- FGEN 0.58
- MACD
- USIO 0.01
- FGEN -0.03
- Stochastic Oscillator
- USIO 63.81
- FGEN 45.59
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.